GRI Bio, Inc. (GRI) 10-Year Financial Performance & Capital Metrics

GRI • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Show more

Revenue $23M
EBITDA -$8M +27.4%
Net Income -$8M +37.0%
EPS (Diluted) -55.21 +99.1%
Gross Margin 48.41%
EBITDA Margin -36.52%
Operating Margin -36.54%
Net Margin -36.41%
ROE -382.52% +92.4%
ROIC -
Debt/Equity 0.03 -45.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.0x book value
✓Efficient asset utilization: 3.9x turnover

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-20.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM98.4%

ROCE

10Y Avg-1193.59%

5Y Avg-1072.07%

3Y Avg-1626.25%

Latest-377.58%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	100K	0	0	0	22.54M
Revenue Growth %	-	-	-	-1%	-	-	-
Cost of Goods Sold+	612	735	100K	0	0	0	11.63M
COGS % of Revenue	-	-	1%	-	-	-	0.52%
Gross Profit+	-612	-735	0	0	0	0	10.91M
Gross Margin %	-	-	-	-	-	-	0.48%
Gross Profit Growth %	-	-0.2%	1%	-	-	-	-
Operating Expenses+	4.31M	3.15M	4.81M	1.06M	2.24M	11.39M	8.23M
OpEx % of Revenue	-	-	48.13%	-	-	-	0.37%
Selling, General & Admin	800.08K	1.27M	1.11M	813K	2M	8.15M	4.47M
SG&A % of Revenue	-	-	11.06%	-	-	-	0.2%
Research & Development	3.51M	1.88M	3.71M	249K	242K	3.23M	3.77M
R&D % of Revenue	-	-	37.07%	-	-	-	0.17%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-4.31M	-3.15M	-4.79M	-1.06M	-2.24M	-11.39M	-8.23M
Operating Margin %	-	-	-47.88%	-	-	-	-0.37%
Operating Income Growth %	-	0.27%	-0.52%	0.78%	-1.11%	-4.09%	0.28%
EBITDA+	-4.31M	-3.15M	-4.71M	-989K	-2.19M	-11.33M	-8.23M
EBITDA Margin %	-	-	-47.13%	-	-	-	-0.37%
EBITDA Growth %	-	0.27%	-0.49%	0.79%	-1.21%	-4.18%	0.27%
D&A (Non-Cash Add-back)	612	735	75K	73K	50K	57K	4K
EBIT	-4.31M	-3.27M	-4.79M	-1.01M	-2.56M	-10.96M	-8.23M
Net Interest Income+	1.06K	-197.03K	-34K	-547K	-653K	-2.08M	25K
Interest Income	1.06K	0	0	0	0	0	25K
Interest Expense	0	197.03K	34K	547K	653K	2.08M	0
Other Income/Expense	1.06K	-310.07K	-34K	-497K	-978K	-1.65M	28K
Pretax Income+	-4.31M	-3.46M	-4.82M	-1.56M	-3.22M	-13.04M	-8.21M
Pretax Margin %	-	-	-48.22%	-	-	-	-0.36%
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-4.31M	-3.46M	-4.82M	-1.56M	-3.22M	-13.04M	-8.21M
Net Margin %	-	-	-48.22%	-	-	-	-0.36%
Net Income Growth %	-	0.2%	-0.39%	0.68%	-1.06%	-3.05%	0.37%
Net Income (Continuing)	-4.31M	-3.46M	-4.82M	-1.56M	-3.22M	-13.04M	-8.21M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-29385.00	-23606.00	-32856.00	-815.80	-165346.00	-6242.18	-55.21
EPS Growth %	-	0.2%	-0.39%	0.98%	-201.68%	0.96%	0.99%
EPS (Basic)	-29385.00	-23606.00	-32856.00	-815.80	-165346.00	-6242.18	-55.21
Diluted Shares Outstanding	24.95K	24.95K	24.95K	324.87K	32.49K	44.18K	183.28K
Basic Shares Outstanding	24.95K	24.95K	24.95K	324.87K	32.49K	44.18K	183.28K
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	637.64K	3.92M	674K	8.13M	312K	2.93M	5.62M
Cash & Short-Term Investments	612.65K	3.82M	109K	7.51M	9K	1.81M	5.03M
Cash Only	612.65K	3.82M	109K	3.7M	9K	1.81M	5.03M
Short-Term Investments	0	0	0	3.81M	0	0	0
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	24.99K	100.86K	565K	619K	303K	1.13M	587K
Total Non-Current Assets+	1.59K	353.9K	281K	206K	71K	22K	124K
Property, Plant & Equipment	1.59K	353.9K	281K	206K	71K	22K	124K
Fixed Asset Turnover	-	-	0.36x	-	-	-	181.76x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0
Total Assets+	639.23K	4.28M	955K	8.34M	383K	2.96M	5.74M
Asset Turnover	-	-	0.10x	-	-	-	3.93x
Asset Growth %	-	5.69%	-0.78%	7.73%	-0.95%	6.72%	0.94%
Total Current Liabilities+	486.29K	807.5K	2.23M	2.44M	1.99M	2.7M	1.64M
Accounts Payable	286.61K	246.33K	1.23M	918K	1.29M	1.41M	897K
Days Payables Outstanding	170.94K	122.33K	4.47K	-	-	-	28.16
Short-Term Debt	0	85.67K	152K	97K	602K	14K	48K
Deferred Revenue (Current)	0	0	81K	62K	5K	0	0
Other Current Liabilities	150.83K	255.81K	424K	1.08M	60K	537K	306K
Current Ratio	1.31x	4.86x	0.30x	3.32x	0.16x	1.09x	3.43x
Quick Ratio	1.31x	4.86x	0.30x	3.32x	0.16x	1.09x	3.43x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	254.36K	184K	72K	14K	0	71K
Long-Term Debt	0	0	14K	0	0	0	0
Capital Lease Obligations	0	254.36K	170K	72K	14K	0	71K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	486.29K	1.06M	2.41M	2.52M	2.01M	2.7M	1.71M
Total Debt+	0	340.02K	336K	169K	673K	14K	119K
Net Debt	-612.65K	-3.48M	227K	-3.53M	664K	-1.79M	-4.91M
Debt / Equity	-	0.11x	-	0.03x	-	0.05x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-16.01x	-140.82x	-1.94x	-3.43x	-5.47x	-
Total Equity+	152.94K	3.21M	-1.45M	5.82M	-1.63M	259K	4.03M
Equity Growth %	-	20.01%	-1.45%	5%	-1.28%	1.16%	14.57%
Book Value per Share	6.13	128.81	-58.28	17.91	-50.02	5.86	22.00
Total Shareholders' Equity	152.94K	3.21M	-1.45M	5.82M	-1.63M	259K	4.03M
Common Stock	11.25K	18.02K	0	0	1K	0	0
Retained Earnings	-4.31M	-7.78M	-12.6M	-21.9M	-18.5M	-31.53M	-39.74M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-2K	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-2.37M	-2.88M	-3.71M	-8.31M	-1.08M	-9.14M	-8.61M
Operating CF Margin %	-	-	-37.06%	-	-	-	-0.38%
Operating CF Growth %	-	-0.22%	-0.29%	-1.24%	0.87%	-7.42%	0.06%
Net Income	-4.31M	-3.46M	-4.82M	-9.3M	-3.22M	-13.04M	-8.21M
Depreciation & Amortization	612	735	75K	73K	50K	57K	4K
Stock-Based Compensation	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	1.48M	420.35K	154K	355K	567K	2.16M	40K
Working Capital Changes	461.31K	159.67K	887K	563K	1.51M	1.68M	-448K
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	286.61K	-40.28K	980K	-308K	897K	2.16M	-387K
Cash from Investing+	-2.2K	0	-2K	-3.84M	-3K	-8K	0
Capital Expenditures	-2.2K	0	-2K	0	-3K	-8K	-396K
CapEx % of Revenue	-	-	0.02%	-	-	-	0.02%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	396K
Cash from Financing+	2.99M	6.09M	-4K	15.75M	1.01M	10.95M	11.83M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	0	0	15.4M	5K	-2.05M	-1K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-2.37M	-2.88M	-3.71M	-8.31M	-1.09M	-9.15M	-8.61M
FCF Margin %	-	-	-37.08%	-	-	-	-0.38%
FCF Growth %	-	-0.22%	-0.29%	-1.24%	0.87%	-7.41%	0.06%
FCF per Share	-95.12	-115.58	-148.62	-25.59	-33.49	-207.05	-46.98
FCF Conversion (FCF/Net Income)	0.55x	0.83x	0.77x	5.33x	0.34x	0.70x	1.05x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2819.85%	-205.81%	-548.02%	-71.45%	-153.45%	-5033.59%	-382.52%
Return on Invested Capital (ROIC)	-	-	-	-150.57%	-253.66%	-	-
Gross Margin	-	-	-	-	-	-	48.41%
Net Margin	-	-	-4822%	-	-	-	-36.41%
Debt / Equity	-	0.11x	-	0.03x	-	0.05x	0.03x
Interest Coverage	-	-16.01x	-140.82x	-1.94x	-3.43x	-5.47x	-
FCF Conversion	0.55x	0.83x	0.77x	5.33x	0.34x	0.70x	1.05x
Revenue Growth	-	-	-	-100%	-	-	-

Frequently Asked Questions

Growth & Financials

GRI Bio, Inc. (GRI) reported $22.5M in revenue for fiscal year 2024.

GRI Bio, Inc. (GRI) grew revenue by 0.0% over the past year. Growth has been modest.

GRI Bio, Inc. (GRI) reported a net loss of $10.0M for fiscal year 2024.

Dividend & Returns

GRI Bio, Inc. (GRI) has a return on equity (ROE) of -382.5%. Negative ROE indicates the company is unprofitable.

GRI Bio, Inc. (GRI) had negative free cash flow of $9.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener